KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Profit After Tax (2019 - 2025)

Aurinia Pharmaceuticals' Profit After Tax history spans 7 years, with the latest figure at $210.8 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 14651.15% year-over-year to $210.8 million; the TTM value through Dec 2025 reached $287.2 million, up 4893.08%, while the annual FY2025 figure was $287.2 million, 4893.08% up from the prior year.
  • Profit After Tax reached $210.8 million in Q4 2025 per AUPH's latest filing, up from $31.6 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $210.8 million in Q4 2025 to a low of -$50.4 million in Q1 2021.
  • Average Profit After Tax over 5 years is -$3.7 million, with a median of -$12.5 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: plummeted 94.27% in 2021, then soared 14651.15% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$33.3 million in 2021, then increased by 21.84% to -$26.0 million in 2022, then fell by 3.18% to -$26.9 million in 2023, then skyrocketed by 105.32% to $1.4 million in 2024, then skyrocketed by 14651.15% to $210.8 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Profit After Tax are $210.8 million (Q4 2025), $31.6 million (Q3 2025), and $21.5 million (Q2 2025).